Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 6Completed 4Not yet recruiting 3Active not recruiting 3Terminated 2Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 128Breast Neoplasms 111Neoplasms 93Neoplasm Metastasis 76Melanoma 70Colorectal Neoplasms 69Leukemia, Myeloid, Acute 66Prostatic Neoplasms 58Multiple Myeloma 53Lung Neoplasms 51Ovarian Neoplasms 49Squamous Cell Carcinoma of Head and Neck 45Recurrence 41Triple Negative Breast Neoplasms 40Carcinoma, Renal Cell 38Carcinoma, Hepatocellular 38Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 34Brain Neoplasms 34Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Lymphoma 30Endometrial Neoplasms 30Head and Neck Neoplasms 28Lymphoma, Large B-Cell, Diffuse 27Leukemia 27Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

NX-13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Colitis, Ulcerative × 1 year × Clear all
NCT05156125 2026-04-30

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Oppilan Pharma Ltd

Phase 2 Terminated
213 enrolled 19 charts
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

NCT05785715 2025-07-01

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

AbbVie

Phase 2 Terminated
81 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡